Search…

Stone Medicine Group (01093): Selective 5-HT2A receptor agonist (SYH2056 tablet) approved for clinical trials in China.

21/11/2025

Zhtng Cijng APP News, Stone Pharmaceutical Group (01093) announced that the group's development of a type 1 new drug, the selective 5-hydroxytryptamine 2A receptor (5-HT2A receptor) agonist (SYH2056 tablets) has been approved by the National Medical Products Administration of the People's Republic of China and can now conduct clinical trials in China.

Latest

2 m ago

Affected by the fall in the prices of gold, silver, and palladium, the stock prices of precious metal mining companies listed in the United States have declined.

4 m ago

The initial value of the November S&P Global Manufacturing PMI in the United States is 51.9, with an expectation of 52, and a previous value of 52.5. The initial value of the November S&P Global Services PMI in the United States is 55, with an expectation of 54.6, and a previous value of 54.8. The initial value of the November S&P Global Composite PMI in the United States is 54.8, with an expectation of 54.6, and a previous value of 54.6.

6 m ago

Ruixing Film (09958) reported a net loss attributable to equity shareholders of approximately 554 million yuan for the 18-month period.

6 m ago

LongXun Technology Co., Ltd. (688486.SH) plans to list in Hong Kong.

7 m ago

After falling for seven consecutive trading days, the stock price of the London Stock Exchange Group rose by 4%.

See all latest